肿瘤免疫检查点抑制剂个体化用药策略研究进展

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (2): 228-232.

肿瘤免疫检查点抑制剂个体化用药策略研究进展

王韦力^1,2，廖萍^1,2，许标波^1,2，周成芳^1,2，谢商宸^1,2，沈冬亚^1,2，贺毅憬^1,2，Howard L. Mcleod ^1,2

¹中南大学湘雅医院临床药理研究所，长沙 410008，湖南； ²中南大学临床药理研究所遗传药理学湖南省重点实验室，长沙 410078，湖南

收稿日期:2016-09-12 修回日期:2016-11-28 出版日期:2017-02-26 发布日期:2017-03-02
通讯作者: Howard L. Mcleod，男，博士生导师，主要研究方向：遗传药理学和临床药理学。 Tel：0731-84805380 E-mail：Howard.McLeod@moffitt.org
作者简介:王韦力，女，硕士研究生，主要研究方向：遗传药理学和临床药理学。 Tel：0731-84805380 E-mail：wwloving@foxmail.com
基金资助:
国家自然科学基金项目（81403022）

Research progress of personalized medicine for immune checkpoint blockades

WANG Weili^1,2，LIAO Ping ^1,2, XU Biaobo ^1,2，ZHOU Chengfang ^1,2, XIE Shangchen ^1,2, SHEN Dongya ^1,2, HE Yijing ^1,2, Howard L. Mcleod ^1,2

¹Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; ²Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, Hunan, China

Received:2016-09-12 Revised:2016-11-28 Online:2017-02-26 Published:2017-03-02

摘要/Abstract

摘要：

免疫检查点抑制剂通过解除机体免疫系统的刹车系统来增强机体的抗肿瘤免疫反应，其长效抗肿瘤效应使得这一新的抗肿瘤方法备受关注。然而，目前免疫检查点抑制剂的总体有效率仅有10%～40%。如何预判这一新治疗方法的临床有效率成为临床关注的重点。根据目前已有的研究，我们认为在肿瘤-免疫相互作用的过程中，有三项重要因素影响了免疫检查点抑制剂在患者中的有效率和临床获益。在本文中，我们将就此三项关键机制展开讨论。

关键词: 免疫治疗, 免疫检查点抑制剂, 个体化医学, PD-1/PD-L1抑制剂

Abstract:

Immune checkpoint blockades, which release the brake of immune system to enhance anti-cancer immune response, stand out in the cancer immunotherapy field due to their remarkable and long-lasting effect. However, the overall response rate for currently proved immune checkpoint inhibitors is only about 10%-40%. How to predict patients' outcome of these drugs has becoming the crucial focus in clinical. Three major components considered as the key to describe the cancer-immune interaction in immune checkpoint therapy will be discussed in this review.

Key words: immunotherapy, immune checkpoint blockades, personalized medicine, PD-1/PD-L1 inhibitors

中图分类号:

R969.1

王韦力，廖萍，许标波，周成芳，谢商宸，沈冬亚，贺毅憬，Howard L. Mcleod. 肿瘤免疫检查点抑制剂个体化用药策略研究进展[J]. 中国临床药理学与治疗学, 2017, 22(2): 228-232.

WANG Weili，LIAO Ping, XU Biaobo，ZHOU Chengfang, XIE Shangchen, SHEN Dongya, HE Yijing, Howard L. Mcleod. Research progress of personalized medicine for immune checkpoint blockades[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 228-232.

参考文献

［1］Sharma P, Allison JP. The future of immune checkpoint therapy［J］. Science, 2015,6230(348):56-61.
［2］Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial［J］. Lancet,2016,387(10031):1909-1920.
［3］Ito A, Kondo S, Tada K, et al. Clinical Development of Immune Checkpoint Inhibitors［J］. Biomed Res Int,2015,2015:1-12.
［4］Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation［J］. New Engl J Med,2011,364(26):2507-2516.
［5］Kumarakulasinghe NB, van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)［J］. Respirology,2015,20(3):370-378.
［6］Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway［J］. New Engl J Med,2016,375(18):1767-1778.
［7］Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer［J］. New Engl J Med,2012,366(26):2443-2454.
［8］Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy［J］. Clin Cancer Res, 2014, 20(19):5064-5074.
［9］Kaufman HL. Precision immunology: the promise of immunotherapy for the treatment of cancer［J］. J Clinical Oncol,2015,33(12):1315-1317.
［10］Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer［J］. Nature, 2013,500(7463):415-421.
［11］Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer［J］. Science, 2015,348(6230):124-128.
［12］Scarpa M, Ruffolo C, Canal F, et al. Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance［J］. Oncotarget,2015,6(41):43472-43482.
［13］Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer［J］. Curr Treat Option On,2015,16(7):30.
［14］Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency［J］. New Engl J Med,2015,372(26):2509-2520.
［15］Zaragoza J, Caille A, Beneton N, et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma［J］. Brit J Dermatol,2016,174(1):146-151.
［16］Ferrucci PF, Gandini S, Battaglia A, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients［J］. Brit J Cancer,2015,112(12):1904-1910.
［17］Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival［J］. Ann Oncol,2013,24(6):1697-1703.
［18］Gebhardt C, Sevko A, Jiang H, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab［J］. Clin Cancer Res,2015,21(24):5453-5459.
［19］Schumacher TN, Schreiber RD. T cell exclusion, immune privilege, and the tumor microenvironment［J］. Science,2015, 348(6230):69-74.
［20］Wang W, Yu D, Sarnaik AA,et al. Biomarkers on melanoma patient T Cells associated with ipilimumab treatment［J］. Ann Dermatol Venereol,2012,140(6/7):448-451.
［21］Deschoolmeester V, Baay M, Van Marck E, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients［J］. BMC immunol,2010,11(1):19.
［22］Berghoff AS, Ricken G, Widhalm G, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases［J］. Histopathology,2015,66(2):289-299.
［23］Broussard EK, Disis ML. TNM staging in colorectal cancer: T is for T cell and M is for memory［J］. J Clin Oncol,2011,29(6):601-603.
［24］Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer［J］. Science,2015,348(6230):62-68.
［25］Galon J, Pages F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force［J］. J Transl Med, 2012,10:205.
［26］Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction［J］. J Clin Oncol,2011,29(6):610-618.
［27］Feng Z, Puri S, Moudgil T, et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma［J］. J Immunother Cancer,2015, 3:47.
［28］Kelderman S, Heemskerk B, van Tinteren H, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma［J］. Cancer Immunol Immunother,2014,63(5):449-458.
［29］Calcinotto A, Filipazzi P, Grioni M, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes［J］. Cancer Res,2012,72(11):2746-2756.
［30］Fischer K, Hoffmann P, Voelkl S,et al.Inhibitory effect of tumor cell-derived lactic acid on human T cells［J］. Blood,109(9):3812-3819.
［31］Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: A magic bullet?［J］. Science,2013,339(6117):286-291.
［32］Coffelt SB, Kersten K, Doornebal CW, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis［J］. Nature,2015,522(7556):345-348.
［33］Zelenay S, van der Veen AG, Bottcher JP, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity［J］. Cell,2015, 162(6):1257-1270.
［34］Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy［J］. Cancer J, 2010,16(4):399-403.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[3]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[4]	李玮, 胡佳丽, 王凯, 贺毅憬. 黑色素瘤免疫治疗的研究现状与展望[J]. 中国临床药理学与治疗学, 2021, 26(9): 1053-1064.
[5]	闵行, 郭梦然, 叶月, 许晓双, 甄东户. 免疫检查点抑制剂对甲状腺功能影响的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(2): 223-229.
[6]	赵全铭，杨洋. 晚期三阴性乳腺癌的药物治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(4): 475-480.
[7]	常香香，韦中玲，郑幸媛，李慧敏，黄来全. 多发性骨髓瘤的治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 107-116.
[8]	张锴婷，陈乃涵. 生物药在肿瘤治疗领域的临床研究进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 32-43.
[9]	蒙秋华，田婧，覃斐章，覃杨，董敏. PD-1/PD-L1通路抑制剂在消化系统肿瘤免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(8): 942-948.
[10]	章晓英，王康，邬莎，郭鹏. 低剂量奥氮平控制抗NMDAR脑炎精神症状的联系分析[J]. 中国临床药理学与治疗学, 2018, 23(11): 1292-1296.
[11]	杨何，张升，辛艳飞. 肿瘤免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2016, 21(9): 1074-1080.
[12]	艾雄飞，杜丹玉，孙立，林森森，袁胜涛. 靶向肿瘤相关巨噬细胞的治疗进展及风险[J]. 中国临床药理学与治疗学, 2016, 21(6): 697-702.
[13]	许标波，贺毅憬，王韦力，周成芳，谢商宸，沈冬亚，Howard L. Mcleod. 肿瘤免疫检查点抑制剂临床治疗的研究进展[J]. 中国临床药理学与治疗学, 2016, 21(2): 218-224.
[14]	陈存国, 李绍波, 王昕昕, 金小红, 童夏生, 赖小英. 特异性免疫治疗对哮喘大鼠白细胞介素-10和CD₄⁺CD₂₅⁺调节性T细胞的影响[J]. 中国临床药理学与治疗学, 2010, 15(8): 871-875.
[15]	李绍波, 金小红, 王昕昕, 赖小英, 童夏生. 特异性免疫治疗对哮喘大鼠转化生长因子-β₁/ Smad 信号通路的影响[J]. 中国临床药理学与治疗学, 2009, 14(11): 1229-1233.